Prognostic relevance of lymph node ratio following pancreaticoduodenectomy for pancreatic cancer

Timothy M. Pawlik, Ana L. Gleisner, John L. Cameron, Jordan M. Winter, Lia Assumpcao, Keith D. Lillemoe, Christopher Wolfgang, Ralph H. Hruban, Richard D. Schulick, Charles J. Yeo, Michael A. Choti

Research output: Contribution to journalArticle

305 Citations (Scopus)

Abstract

Background: The presence or absence of lymph node metastases is known to be an important prognostic factor for patients with pancreatic cancer. Few studies have investigated the ratio of the number of lymph nodes harboring metastatic cancer to the total number of lymph nodes examined (lymph node ratio [LNR]) with regard to outcome after pancreaticoduodenectomy for ductal cancer of the pancreas. Methods: Between 1995 and 2005, a total of 905 patients underwent pancreaticoduodenectomy for pancreatic adenocarcinoma. Demographics, operative data, number of lymph nodes evaluated, number of lymph nodes with metastatic carcinoma, LNR, pathologic margin status, and long-term survival were analyzed. Results: There were 187 (20.7%) of the 905 patients who had negative peripancreatic lymph nodes (N0), whereas 718 (79.3%) of the 905 patients had lymph node metastases (N1). The median number of lymph nodes evaluated in the N0 group was 15 versus 18 in the N1 group (P = .12). At median follow-up of 24 months, the median survival for all patients was 17.4 months, and the 5-year actuarial survival rate was 16.1%. Patients with lymph node metastases had a shorter median overall survival (16.5 months) compared with patients with negative lymph nodes (25.3 months; P = .001). Compared with the total number of lymph nodes examined or total number of lymph node metastases, LNR was the most compelling predictor of survival. As the LNR increased, median overall survival decreased (LNR = 0, 25.3 months; LNR > 0 to 0.2, 21.7 months; LNR > 0.2 to 0.4, 15.3 months; LNR > 0.4, 12.2 months; P = .001). After adjusting for other factors associated with survival, LNR remained an independent predictor of overall survival (P < .001). Conclusions: After pancreaticoduodenectomy for adenocarcinoma of the pancreas, LNR was one of the most powerful predictors of survival. LNR should be considered when stratifying patients in future clinical trials.

Original languageEnglish (US)
Pages (from-to)610-618
Number of pages9
JournalSurgery
Volume141
Issue number5
DOIs
StatePublished - May 2007

Fingerprint

Pancreaticoduodenectomy
Pancreatic Neoplasms
Lymph Nodes
Survival
Neoplasm Metastasis
Adenocarcinoma

ASJC Scopus subject areas

  • Surgery

Cite this

Pawlik, T. M., Gleisner, A. L., Cameron, J. L., Winter, J. M., Assumpcao, L., Lillemoe, K. D., ... Choti, M. A. (2007). Prognostic relevance of lymph node ratio following pancreaticoduodenectomy for pancreatic cancer. Surgery, 141(5), 610-618. https://doi.org/10.1016/j.surg.2006.12.013

Prognostic relevance of lymph node ratio following pancreaticoduodenectomy for pancreatic cancer. / Pawlik, Timothy M.; Gleisner, Ana L.; Cameron, John L.; Winter, Jordan M.; Assumpcao, Lia; Lillemoe, Keith D.; Wolfgang, Christopher; Hruban, Ralph H.; Schulick, Richard D.; Yeo, Charles J.; Choti, Michael A.

In: Surgery, Vol. 141, No. 5, 05.2007, p. 610-618.

Research output: Contribution to journalArticle

Pawlik, TM, Gleisner, AL, Cameron, JL, Winter, JM, Assumpcao, L, Lillemoe, KD, Wolfgang, C, Hruban, RH, Schulick, RD, Yeo, CJ & Choti, MA 2007, 'Prognostic relevance of lymph node ratio following pancreaticoduodenectomy for pancreatic cancer', Surgery, vol. 141, no. 5, pp. 610-618. https://doi.org/10.1016/j.surg.2006.12.013
Pawlik TM, Gleisner AL, Cameron JL, Winter JM, Assumpcao L, Lillemoe KD et al. Prognostic relevance of lymph node ratio following pancreaticoduodenectomy for pancreatic cancer. Surgery. 2007 May;141(5):610-618. https://doi.org/10.1016/j.surg.2006.12.013
Pawlik, Timothy M. ; Gleisner, Ana L. ; Cameron, John L. ; Winter, Jordan M. ; Assumpcao, Lia ; Lillemoe, Keith D. ; Wolfgang, Christopher ; Hruban, Ralph H. ; Schulick, Richard D. ; Yeo, Charles J. ; Choti, Michael A. / Prognostic relevance of lymph node ratio following pancreaticoduodenectomy for pancreatic cancer. In: Surgery. 2007 ; Vol. 141, No. 5. pp. 610-618.
@article{d0dbf5f55050471fb5f37d6954ab76dc,
title = "Prognostic relevance of lymph node ratio following pancreaticoduodenectomy for pancreatic cancer",
abstract = "Background: The presence or absence of lymph node metastases is known to be an important prognostic factor for patients with pancreatic cancer. Few studies have investigated the ratio of the number of lymph nodes harboring metastatic cancer to the total number of lymph nodes examined (lymph node ratio [LNR]) with regard to outcome after pancreaticoduodenectomy for ductal cancer of the pancreas. Methods: Between 1995 and 2005, a total of 905 patients underwent pancreaticoduodenectomy for pancreatic adenocarcinoma. Demographics, operative data, number of lymph nodes evaluated, number of lymph nodes with metastatic carcinoma, LNR, pathologic margin status, and long-term survival were analyzed. Results: There were 187 (20.7{\%}) of the 905 patients who had negative peripancreatic lymph nodes (N0), whereas 718 (79.3{\%}) of the 905 patients had lymph node metastases (N1). The median number of lymph nodes evaluated in the N0 group was 15 versus 18 in the N1 group (P = .12). At median follow-up of 24 months, the median survival for all patients was 17.4 months, and the 5-year actuarial survival rate was 16.1{\%}. Patients with lymph node metastases had a shorter median overall survival (16.5 months) compared with patients with negative lymph nodes (25.3 months; P = .001). Compared with the total number of lymph nodes examined or total number of lymph node metastases, LNR was the most compelling predictor of survival. As the LNR increased, median overall survival decreased (LNR = 0, 25.3 months; LNR > 0 to 0.2, 21.7 months; LNR > 0.2 to 0.4, 15.3 months; LNR > 0.4, 12.2 months; P = .001). After adjusting for other factors associated with survival, LNR remained an independent predictor of overall survival (P < .001). Conclusions: After pancreaticoduodenectomy for adenocarcinoma of the pancreas, LNR was one of the most powerful predictors of survival. LNR should be considered when stratifying patients in future clinical trials.",
author = "Pawlik, {Timothy M.} and Gleisner, {Ana L.} and Cameron, {John L.} and Winter, {Jordan M.} and Lia Assumpcao and Lillemoe, {Keith D.} and Christopher Wolfgang and Hruban, {Ralph H.} and Schulick, {Richard D.} and Yeo, {Charles J.} and Choti, {Michael A.}",
year = "2007",
month = "5",
doi = "10.1016/j.surg.2006.12.013",
language = "English (US)",
volume = "141",
pages = "610--618",
journal = "Surgery (United States)",
issn = "0039-6060",
publisher = "Mosby Inc.",
number = "5",

}

TY - JOUR

T1 - Prognostic relevance of lymph node ratio following pancreaticoduodenectomy for pancreatic cancer

AU - Pawlik, Timothy M.

AU - Gleisner, Ana L.

AU - Cameron, John L.

AU - Winter, Jordan M.

AU - Assumpcao, Lia

AU - Lillemoe, Keith D.

AU - Wolfgang, Christopher

AU - Hruban, Ralph H.

AU - Schulick, Richard D.

AU - Yeo, Charles J.

AU - Choti, Michael A.

PY - 2007/5

Y1 - 2007/5

N2 - Background: The presence or absence of lymph node metastases is known to be an important prognostic factor for patients with pancreatic cancer. Few studies have investigated the ratio of the number of lymph nodes harboring metastatic cancer to the total number of lymph nodes examined (lymph node ratio [LNR]) with regard to outcome after pancreaticoduodenectomy for ductal cancer of the pancreas. Methods: Between 1995 and 2005, a total of 905 patients underwent pancreaticoduodenectomy for pancreatic adenocarcinoma. Demographics, operative data, number of lymph nodes evaluated, number of lymph nodes with metastatic carcinoma, LNR, pathologic margin status, and long-term survival were analyzed. Results: There were 187 (20.7%) of the 905 patients who had negative peripancreatic lymph nodes (N0), whereas 718 (79.3%) of the 905 patients had lymph node metastases (N1). The median number of lymph nodes evaluated in the N0 group was 15 versus 18 in the N1 group (P = .12). At median follow-up of 24 months, the median survival for all patients was 17.4 months, and the 5-year actuarial survival rate was 16.1%. Patients with lymph node metastases had a shorter median overall survival (16.5 months) compared with patients with negative lymph nodes (25.3 months; P = .001). Compared with the total number of lymph nodes examined or total number of lymph node metastases, LNR was the most compelling predictor of survival. As the LNR increased, median overall survival decreased (LNR = 0, 25.3 months; LNR > 0 to 0.2, 21.7 months; LNR > 0.2 to 0.4, 15.3 months; LNR > 0.4, 12.2 months; P = .001). After adjusting for other factors associated with survival, LNR remained an independent predictor of overall survival (P < .001). Conclusions: After pancreaticoduodenectomy for adenocarcinoma of the pancreas, LNR was one of the most powerful predictors of survival. LNR should be considered when stratifying patients in future clinical trials.

AB - Background: The presence or absence of lymph node metastases is known to be an important prognostic factor for patients with pancreatic cancer. Few studies have investigated the ratio of the number of lymph nodes harboring metastatic cancer to the total number of lymph nodes examined (lymph node ratio [LNR]) with regard to outcome after pancreaticoduodenectomy for ductal cancer of the pancreas. Methods: Between 1995 and 2005, a total of 905 patients underwent pancreaticoduodenectomy for pancreatic adenocarcinoma. Demographics, operative data, number of lymph nodes evaluated, number of lymph nodes with metastatic carcinoma, LNR, pathologic margin status, and long-term survival were analyzed. Results: There were 187 (20.7%) of the 905 patients who had negative peripancreatic lymph nodes (N0), whereas 718 (79.3%) of the 905 patients had lymph node metastases (N1). The median number of lymph nodes evaluated in the N0 group was 15 versus 18 in the N1 group (P = .12). At median follow-up of 24 months, the median survival for all patients was 17.4 months, and the 5-year actuarial survival rate was 16.1%. Patients with lymph node metastases had a shorter median overall survival (16.5 months) compared with patients with negative lymph nodes (25.3 months; P = .001). Compared with the total number of lymph nodes examined or total number of lymph node metastases, LNR was the most compelling predictor of survival. As the LNR increased, median overall survival decreased (LNR = 0, 25.3 months; LNR > 0 to 0.2, 21.7 months; LNR > 0.2 to 0.4, 15.3 months; LNR > 0.4, 12.2 months; P = .001). After adjusting for other factors associated with survival, LNR remained an independent predictor of overall survival (P < .001). Conclusions: After pancreaticoduodenectomy for adenocarcinoma of the pancreas, LNR was one of the most powerful predictors of survival. LNR should be considered when stratifying patients in future clinical trials.

UR - http://www.scopus.com/inward/record.url?scp=34247218441&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34247218441&partnerID=8YFLogxK

U2 - 10.1016/j.surg.2006.12.013

DO - 10.1016/j.surg.2006.12.013

M3 - Article

C2 - 17462460

AN - SCOPUS:34247218441

VL - 141

SP - 610

EP - 618

JO - Surgery (United States)

JF - Surgery (United States)

SN - 0039-6060

IS - 5

ER -